Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.47 |
| ▸ | ANPEP | P15144 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 10/20 | 0.46 |
| ▸ | ERAP1 | Q9NZ08 | 4/20 | 0.46 |
| ▸ | LNPEP | Q9UIQ6 | 4/20 | 0.45 |
| ▸ | ERAP2 | Q6P179 | 3/20 | 0.45 |
| ▸ | CTSB | P07858 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16984894 | 0.95 | LNPEP (0.44) | MMEANPEPCTSLERAP1LNPEP | |
| SCHEMBL16984914 | 0.93 | LNPEP (0.46) | MMEANPEPCTSLERAP1LNPEP | |
| SCHEMBL16984895 | 0.92 | MME (0.48) | MMEANPEPCTSLCTSBPOLB | |
| SCHEMBL16970519 | 0.89 | ACE (0.54) | MMEERAP1LNPEPERAP2 | |
| SCHEMBL16984886 | 0.88 | CTSC (0.45) | MMEANPEPCTSLPOLBTACR1 | |
| SCHEMBL16925150 | 0.88 | MME (0.50) | MMEANPEPCTSLCTSBPOLB | |
| SCHEMBL16984878 | 0.88 | CTSL (0.51) | CTSLERAP1ERAP2CTSB | |
| SCHEMBL16984915 | 0.86 | CTSL (0.43) | MMEANPEPCTSLERAP1LNPEP | |
| SCHEMBL16984799 | 0.86 | CTSC (0.47) | MMEANPEPCTSLCTSBPOLB | |
| SCHEMBL16970557 | 0.86 | ACE (0.46) | MMEERAP1LNPEPERAP2CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150218212-A1 | FLUORINATED EPOXYKETONE-BASED TETRAPEPTIDE COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | FLUORINOV PHARMA INC. (CA) | 2015-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218212-A1 | FLUORINATED EPOXYKETONE-BASED TETRAPEPTIDE COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | PSMA1, PSMB1, PSMB11 | MME 192/4885ANPEP 119/4885CTSL 1335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.